Horizon, Ubiquigent Enter Ubiquitin Research Pact

Horizon Discovery Group plc has entered into a collaboration agreement with Ubiquigent Ltd. for the use of Horizon’s X-MAN cell lines as part of its ubiquitin system focused drug discovery services. This collaboration aims to provide more complete research solutions to support commercial and academic partners with ubiquitin system focused drug discovery programs. 
 
The ubiquitin system offers new drug discovery target opportunities across multiple therapeutic areas. It provides access to drug discovery services, research tools and chemistry required to support its partners ubiquitin system-focused drug discovery programs.
 
Horizon’s X-MAN cell line range represents an extensive bank of genetically defined and highly validated human cell line models that accurately exhibit disease-causing genetics and are applied in research and clinical applications to advance human health.
 
Thomas Moser, vice president products, Horizon Discovery Group plc, said, “By partnering, Horizon and Ubiquigent are now in a position to provide a more comprehensive package to academic and commercial researchers working in the promising ubiquitin system area. This agreement further underscores the value of Horizon’s X-MAN cell line collection and highlights the impact our models are having on the research community.”
 
Jason Mundin, commercial director, Ubiquigent, said,“Ubiquigent’s first class experience and deep technical capabilities have enabled us to develop an extensive and highly valuable ubiquitin system focused Drug Discovery Service platform for our clients. We are pleased now to provide access Horizon’s unique collection of gene edited cell lines to further enable and expand our service offering.”